Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Viking Global Investors LP, a ten percent owner of BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold 3,500,000 shares of common stock on June 27, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $44, totaling approximately $154 million. The sale comes as BridgeBio’s stock has shown remarkable strength, delivering a 70% return over the past year and trading near its 52-week high of $45.48.
Following the transaction, Viking Global Investors LP directly holds 18,555,375 shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). With a market capitalization of $8.1 billion and a strong current ratio of 4.57, indicating solid liquidity, the company appears well-positioned financially. According to InvestingPro analysis, BridgeBio is currently trading slightly above its Fair Value, with 11 more exclusive insights available to subscribers.
In other recent news, BridgeBio Pharma has announced a significant $300 million royalty sale involving its acoramidis drug, marketed as Attruby in the U.S. and Beyontra in Europe. The company sold 60% of its European royalties to HealthCare Royalty and Blue Owl Capital, which will help strengthen its balance sheet and support ongoing U.S. operations and late-stage R&D programs. This transaction stems from a licensing agreement with Bayer (OTC:BAYRY), which includes upfront and milestone payments along with royalties in the low 30% range of net sales. Analysts from Raymond (NSE:RYMD) James and Citi have reiterated their positive outlooks on BridgeBio, maintaining Outperform and Buy ratings, respectively, with price targets of $57.00 and $58.00. Wolfe Research has initiated coverage with an Outperform rating and a price target of $49.00, projecting significant revenue growth for the company in the coming years. H.C. Wainwright also maintains a Buy rating, raising its price target to $56.00, reflecting optimism about BridgeBio’s financial prospects and sales momentum. These developments indicate analysts’ confidence in BridgeBio’s potential, driven by its strategic financial moves and strong market positioning of acoramidis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.